Finder makes money from featured partners, but editorial opinions are our own.

How to buy Merck-and-Company (MRK) shares in Australia

Learn how to easily invest in Merck-and-Company shares.

Merck & Company Inc (MRK) is a leading drug manufacturers - general business with stocks listed in the US. It opened the day at US$128.84 after a previous close of US$129.49. During the day the price has varied from a low of USD125.74 to a high of USD129.08. The latest price was USD126.09 (25 minute delay). Merck-and-Company is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Merck-and-Company

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Merck-and-Company. Find the share by name or ticker symbol: MRK. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Merck-and-Company reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$129.49, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Merck-and-Company, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Merck-and-Company. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Merck-and-Company stock price (NYSE:MRK)

Use our graph to track the performance of MRK stocks over time.

Have Merck-and-Company's shares ever split?

Merck-and-Company's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before the split, the next day you would own 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.

Merck-and-Company shares at a glance

Information last updated 2024-05-28.
OpenUS$128.84
HighUS$129.08
LowUS$125.74
CloseUS$126.09
Previous closeUS$129.49
Change US$-3.4
Change % -2.6257%
Volume 9,705,072
Information last updated 2024-05-23.
52-week rangeUS$97.8068 - US$133.1
50-day moving average US$127.583
200-day moving average US$115.198
Target priceUS$141.42
PE ratio 145.6667
Dividend yield US$2.96 (2.35%)
Earnings per share (TTM) US$0.9

Merck-and-Company share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Merck-and-Company price performance over time

Historical closes compared with the last close of $126.09

1 week (2024-05-22) -3.82%
1 month (2024-04-29) -3.10%
3 months (2024-02-29) -0.83%
6 months (2023-11-29) 24.68%
1 year (2023-05-26) 13.52%
2 years (2022-05-27) 35.46%
3 years (2021-05-28) 74.12%
5 years (2019-05-29) 66.51%

Compare trading platforms to buy Merck-and-Company shares

Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
CFD service. Capital at risk.
Join the world's biggest social trading network when you trade stocks, commodities and currencies from the one account.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: 10 no-brokerage US or ASX market trades in the first 180 days + 7% p.a. on uninvested cash with first deposit of any amount, plus US$30 TSLA + US$30 NVDA shares with deposits up to AU$2000. T&Cs apply.
Trade Australian, US and Asian stocks with no minimum deposit on Tiger Broker’s feature-packed platform.
CMC Invest
Finder Award
CMC Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, ETFs
$0 brokerage on US, UK, Canadian and Japanese markets (FX spreads apply).
Trade over 45,000 shares and ETFs from Australia and 15 major global markets. Plus, buy Aussie shares or ETFs for $0 brokerage up to $1,000 (First buy order of each security, each day - excludes margin loan settled trades).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Global shares, Options trading, US shares, ETFs
Get 30 days of $0 brokerage fees when you open your account. Receive $50 of TSLA shares and a $50 trading voucher when you deposit $200. T&Cs apply.
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Saxo Invested
Saxo Invested
US$1
0.25%
ASX shares, Global shares, Options trading, US shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Merck-and-Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Merck-and-Company under- or over-valued?

Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-Company's P/E ratio

Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 146x. In other words, Merck-and-Company shares trade at around 146x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Merck-and-Company's PEG ratio

Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1008. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Merck-and-Company's EBITDA

Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$21.2 billion (£16.6 billion).

The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure stock profitability.

Merck-and-Company share price volatility

Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as US$97.8068 up to US$133.1. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.402. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).

Merck-and-Company financials

Revenue TTM US$61.4 billion
Operating margin TTM 42.47%
Gross profit TTM US$42.1 billion
Return on assets TTM 10.26%
Return on equity TTM 5.31%
Profit margin 3.76%
Book value 15.937
Market capitalisation US$332.1 billion

TTM: trailing 12 months

Merck-and-Company share dividends

Dividend payout ratio: 138.25% of net profits

Recently Merck-and-Company has paid out, on average, around 138.25% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.35% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.96 per share.

Merck-and-Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Merck-and-Company's most recent dividend payout was on 4 April 2024. The latest dividend was paid out to all shareholders who bought their shares by 13 March 2024 (the "ex-dividend date").

Merck-and-Company's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-Company.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Merck-and-Company's total ESG risk score

Total ESG risk: 28.35

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-Company's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Merck-and-Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Merck-and-Company's environmental score

Environmental score: 3.15/100

Merck-and-Company's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Merck-and-Company's social score

Social score: 15.55/100

Merck-and-Company's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Merck-and-Company's governance score

Governance score: 12.65/100

Merck-and-Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Merck-and-Company's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-Company hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Merck & Company Inc was last rated for ESG on: 2019-01-01.

Total ESG score 28.35
Total ESG percentile 47.16
Environmental score 3.15
Environmental score percentile 4
Social score 15.55
Social score percentile 4
Governance score 12.65
Governance score percentile 4
Level of controversy 3

Merck-and-Company overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Frequently asked questions

More guides on Finder

Ask a Question

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our 1. Terms Of Service and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site